J&J scores EU approval for Tecvayli combo in second line
Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.
AI, genomics expert leaves Pathos AI, will advise Pfizer
Pfizer is creating the role of AI Scholar for computational biologist Eric Schadt, who is leaving Pathos AI to start a new stealth venture.
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhi...
AC Immune has announced positive interim results from its Ph 1 study of ACI-19764 – a NLRP3 inflammasome inhibitor targeting chronic inflammation.
Akeso and CStone secure China clearances for next-generation...
Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.
Bioptimus, Cancer Research Horizons partner on AI-powered pr...
Bioptimus, a global AI biotech company, has announced a partnership with Cancer Research Horizons, the innovation engine of Cancer Research UK.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The MFN effect: what payers expect and how Pharma should res...
A live webinar and audience Q&A with practical insights from global payer research and leading payer experts
The Pharmaceutical Launch Excellence Summit
Where pharma leaders share strategies for successful drug launches.
Inizio Launches Connected Insights to Transform Global Medic...
Expanded APAC expertise, enhanced global infrastructure, and AI-enabled innovation to help life sciences organizations
9th Lab Asset & Facility Management Summit
Enabling Leaner, Smarter & More Resilient R&D Labs
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.